[Drug Therapy for Glioblastoma:Standard and Novel Treatments].

Authors

Yoshihiro Otani, Shuichiro Hirano, Joji Ishida, Shota Tanaka

Published in

No shinkei geka. Neurological surgery. Volume 54. Issue 4. Pages 737-744.

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor, with a poor prognosis despite advances in multimodal treatment. Current standard of care includes maximal safe resection and radiotherapy with concomitant and adjuvant temozolomide, which is called the Stupp regimen. Tumor-treating fields are incorporated into standard therapies and have demonstrated survival benefits in newly diagnosed GBM. Bevacizumab improves progression-free survival; however, its effect on overall survival remains limited. Recent advances in comprehensive molecular analyses have accelerated the development of novel therapies for GBM. Oncolytic virotherapy has emerged as a promising strategy for inducing direct tumor lysis and antitumor immunity. Immune checkpoint inhibitors, dendritic cell vaccines, CAR-T cell therapy, and gene therapy have been actively investigated. Precision oncology approaches based on genomic profiling, including basket and umbrella trials, are expanding the therapeutic possibilities for selected patients with actionable alterations.

PMID:
42604770
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.